Effect of Acetazolamide on Obesity-Induced Glomerular Hyperfiltration: A Randomized Controlled Trial

Boris Zingerman, Michal Herman-Edelstein, Arie Erman, Sarit Bar Sheshet Itach, Yaacov Ori, Benaya Rozen-Zvi, Uzi Gafter, Avry Chagnac, Boris Zingerman, Michal Herman-Edelstein, Arie Erman, Sarit Bar Sheshet Itach, Yaacov Ori, Benaya Rozen-Zvi, Uzi Gafter, Avry Chagnac

Abstract

Aims: Obesity is an important risk factor for the development of chronic kidney disease. One of the major factors involved in the pathogenesis of obesity-associated kidney disease is glomerular hyperfiltration. Increasing salt-delivery to the macula densa is expected to decrease glomerular filtration rate (GFR) by activating tubuloglomerular feedback. Acetazolamide, a carbonic anhydrase inhibitor which inhibits salt reabsorption in the proximal tubule, increases distal salt delivery. Its effects on obesity-related glomerular hyperfiltration have not previously been studied. The aim of this investigation was to evaluate whether administration of acetazolamide to obese non diabetic subjects reduces glomerular hyperfiltration.

Materials and methods: The study was performed using a randomized double-blind crossover design. Obese non-diabetic men with glomerular hyperfiltration were randomized to receive intravenously either acetazolamide or furosemide at equipotent doses. Twelve subjects received the allocated medications. Two weeks later, the same subjects received the drug which they had not received during the first study. Inulin clearance, p-aminohippuric acid clearance and fractional lithium excretion were measured before and after medications administration. The primary end point was a decrease in GFR, measured as inulin clearance.

Results: GFR decreased by 21% following acetazolamide and did not decrease following furosemide. Renal vascular resistance increased by 12% following acetazolamide, while it remained unchanged following furosemide administration. Natriuresis increased similarly following acetazolamide and furosemide administration. Sodium balance was similar in both groups.

Conclusions: Intravenous acetazolamide decreased GFR in obese non-diabetic men with glomerular hyperfiltration. Furosemide, administered at equipotent dose, did not affect GFR, suggesting that acetazolamide reduced glomerular hyperfiltration by activating tubuloglomerular feedback.

Trial registration: ClinicalTrials.gov NCT01146288.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Investigation's flowchart.
Fig 1. Investigation's flowchart.
Fig 2. GFR before (Baseline) and after…
Fig 2. GFR before (Baseline) and after (Post) acetazolamide and furosemide administration.
GFR decreased by 21% following acetazolamide and remained unchanged following furosemide.
Fig 3. Change in GFR following acetazolamide…
Fig 3. Change in GFR following acetazolamide administration as a function of baseline GFR.
Baseline GFR and the change in GFR following acetazolamide were inversely correlated.
Fig 4. Urinary sodium excretion rate before…
Fig 4. Urinary sodium excretion rate before (Baseline) and after (Post) acetazolamide and furosemide administration.
Natriuresis increased similarly following acetazolamide and furosemide administration.

References

    1. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. (2008) Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008; 73: 19–33.
    1. Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. (2001) Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59:1498–509.
    1. Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezène F et al. (2001) Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 37:720–7.
    1. Kataoka H, Ohara M, Shibui K, Sato M, Suzuki T, Amemiya N et al. (2012) Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters. Clin Exp Nephrol 16:706–12. 10.1007/s10157-012-0613-7
    1. González E, Gutiérrez E, Morales E, Hernández E, Andres A, Bello I et al. (2005) Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int 68:263–70.
    1. Meier-Kriesche H-U, Arndorfer JA, Kaplan B. (2002) The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 73:70–4.
    1. Brøchner-Mortensen J, Rickers H, Balslev I. (1980) Renal function and body composition before and after intestinal bypass operation in obese patients. Scand J Clin Lab Invest 40:695–702.
    1. Reisin E, Messerli FG, Ventura HO, Frohlich ED. (1987) Renal haemodynamic studies in obesity hypertension. J Hypertens 5:397–400.
    1. Ribstein J, du Cailar G, Mimran A. (1995) Combined renal effects of overweight and hypertension. Hypertension 26:610–5.
    1. Porter LE, Hollenberg NK. (1998) Obesity, salt intake, and renal perfusion in healthy humans. Hypertension 32:144–8.
    1. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. (2000) Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278:F817–22.
    1. Pecly IMD, Genelhu V, Francischetti EA. (2006) Renal functional reserve in obesity hypertension. Int J Clin Pract 60:1198–203.
    1. Krikken JA, Lely AT, Bakker SJL, Navis G. (2007) The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 71:260–5.
    1. Chagnac A, Herman M, Zingerman B, Erman A, Rozen-Zvi B, Hirsh J et al. (2008) Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 23:3946–52. 10.1093/ndt/gfn379
    1. Wuerzner G, Pruijm M, Maillard M, Bovet P, Renaud C, Burnier M et al. (2010) Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population. Am J Kidney Dis 56: 303–12. 10.1053/j.ajkd.2010.03.017
    1. Kwakernaak Arjan J., Zelle Dorien M., Bakker Stephan J.L., and Navis Gerjan. Central Body Fat Distribution Associates with Unfavorable Renal Hemodynamics Independent of Body Mass Index. J Am Soc Nephrol 24: 987–994, 2013. 10.1681/ASN.2012050460
    1. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y (2003) The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14:1480–6.
    1. Praga M. Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. (2005) Nephrol Dial Transplant 20:2594–7.
    1. Ritz E, Koleganova N, Piecha G. (2011) Is there an obesity-metabolic syndrome related glomerulopathy? Curr Opin Nephrol Hypertens 20:44–9. 10.1097/MNH.0b013e3283414ca1
    1. Wahba IM, Mak RH. (2007) Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2:550–62.
    1. D’Agati VD, Markowitz GS. (2008) Supersized kidneys: Lessons from the preclinical obese kidney. Kidney Int 73:909–10. 10.1038/ki.2008.42
    1. Bayliss G, Weinrauch LA, D’Elia JA. (2012) Pathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy. Curr Diab Rep 12: 440–6. 10.1007/s11892-012-0288-1
    1. Palatini P. (2012) Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 27: 1708–14. 10.1093/ndt/gfs037
    1. Sasson AN, Cherney DZ. (2012) Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes 3: 1–6. 10.4239/wjd.v3.i1.1
    1. Praga M. (2005) Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant 20: 2594–7.
    1. Tucker BJ, Steiner RW, Gushwa LC, Blantz RC. (1978) Studies on the tubuloglomerular feedback system in the rat. The mechanism of reduction in filtration rate with benzolamide. J Clin Invest 62: 993–1004.
    1. Puschett JB, Goldberg M. (1969) The relationship between the renal handling of phosphate and bicarbonate in man. J Lab Clin Med 73: 956–69.
    1. Colussi G, Rombolà G, Surian M, De Ferrari ME, Airaghi C, Benazzi E et al. (1989) Effects of acute administration of acetazolamide and frusemide on lithium clearance in humans. Nephrol Dial Transplant 4: 707–12.
    1. Skøtt P, Hommel E, Bruun NE, Arnold-Larsen S, Parving HH. (1989) The acute effect of acetazolamide on and proximal tubular reabsorption of sodium and water in normal man. Scand J Clin Lab Invest 49: 583–7.
    1. Guidi E, Colussi G, Rombolà G, Airaghi C, Minetti E, Malberti F et al. (1995) Evaluation of the tubuloglomerular feedback system in human subjects. Exp Nephrol 3: 61–4.
    1. Hannedouche T, Lazaro M, Delgado AG, Boitard C, Lacour B, Grünfeld JP. (1991) Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients. Clin Sci (Lond) 81: 457–64.
    1. Steele TH, Manuel MA, Boner G. (1975) Diuretics, urate excretion and sodium reabsorption: effect of acetazolamide and urinary alkalinization. Nephron 14: 49–61.
    1. Guidi E, Cozzi MG, Minetti EE, Civati G, Busnach G, Brando B. (2001) Effect of familial hypertension on glomerular hemodynamics and tubulo-glomerular feedback after uninephrectomy. Am J Hypertens 14: 121–128
    1. Slomowitz LA, Bergamo R, Hirschberg R, Grosvenor M, Kopple JD. (1996) Enalapril attenuates the renal hemodynamic effect of acetazolamide in patients with diabetes mellitus: possible implications for tubuloglomerular feedback. Am J Nephrol 16: 315–9.
    1. Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A et al. (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587–97. 10.1161/CIRCULATIONAHA.113.005081
    1. Wright FS, Schnermann J. (1974) Interference with feedback control of by furosemide, triflocin, and cyanide. J Clin Invest 53: 1695–708.
    1. Gutsche HU, Brunkhorst R, Müller-Ott K, Franke H, Niedermayer W. (1984) Effect of diuretics on the tubuloglomerular feedback response. Can J Physiol Pharmacol 62: 412–7.
    1. Johnston PA, Kau ST. (1992) The effect of loop of Henle diuretics on the tubuloglomerular feedback mechanism. Methods Find Exp Clin Pharmacol 14: 523–9.
    1. Masud T, Manatunga A, Cotsonis G, Mitch WE. (2002) The precision of estimating protein intake of patients with chronic renal failure. Kidney Int 62: 1750–6.
    1. Persson AE, Wright FS. (1982) Evidence for feedback mediated reduction of during infusion of acetazolamide. Acta Physiol Scand 114: 1–7.
    1. Mathisen O, Raeder M, Sejersted OM, Kiil F. (1976) Effect of acetazolamide on glomerular balance and renal metabolic rate. Scand J Clin Lab Invest 36: 617–25.
    1. Cogan MG, Rector FC. (1982) Determinants of proximal bicarbonate, chloride, and water reabsorption during carbonic anhydrase inhibition. Am J Physiol 242: F274–84.
    1. Yeyati NL, Altenberg GA, Adrogué HJ. (1992) Mechanism of acetazolamide-induced rise in renal vascular resistance assessed in the dog whole kidney. Ren Physiol Biochem 15: 99–105.
    1. Munger KA, Kost CK, Brenner BM M DA. The renal circulations and glomerular ultrafiltration In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, editors. Brenner and Rector’s the Kidney, Ninth Edition Philadelphia, Saunders-Elsevier Inc, 2012; pp 94–137.
    1. Leyssac PP, Karlsen FM, Skøtt O. (1991) Dynamics of intrarenal pressures and glomerular filtration rate after acetazolamide. Am J Physiol. 261(1 Pt 2): F169–78.
    1. Birtch AG. (1967) Redistribution of renal blood flow produced by furosemide and ethacrynic acid. Circ Res 21: 869–78.
    1. Puschett JB and Goldberg M. (1968) The acute effects of furosemide on acid and electrolyte excretion in man. J Lab Clin Med 71: 666–77.
    1. Ludens JH. (1968) Enhancement of renal blood flow by furosemide. J Pharmacol Exp Ther 163: 456–460.
    1. Gerber JG and Nies AS. (1980) Furosemide-induced vasodilation—importance of the state of hydration and filtration. Kidney Int 18: 454–459.
    1. Gerber JG. (1983) Role of prostaglandins in the hemodynamic and tubular effects of furosemide. Fed Proc 42: 1707–10.
    1. Andreasen F, Lauridsen IN, Hansen FA, Christensen S, Steiness E. (1989) Dose dependency of furosemide-induced sodium excretion. J Pharmacol Exp Ther 248: 1182–8.
    1. Boer WH, Fransen R, Shirley DG, Walter SJ, Boer P, Koomans HA. (1995) Evaluation of the lithium clearance method: direct analysis of tubular lithium handling by micropuncture. Kidney Int 47: 1023–30.
    1. Boer WH, Koomans HA, Beutler JJ, Gaillard CA, Rabelink AJ, Dorhout Mees EJ. (1989) Small intra- and large inter-individual variability in lithium clearance in humans. Kidney Int 35: 1183–8.
    1. Koomans HA, Boer WH, Dorhout Mees EJ. (1989) Evaluation of lithium clearance as a marker of proximal tubule sodium handling. Kidney Int 36:2–12.
    1. Dorhout Mees EJ, Beutler JJ, Boer WH, Koomans HA. (1990) Does lithium clearance reflects distal delivery in humans? Analysis with furosemide infusion. Am J Physiol 258: F1100–F1104.
    1. Radtke HW, Rumrich G, Kinne-Saffran E and Ullrich KJ. (1972) Dual action of acetazolamide and furosemide on proximal volume absorption in the rat kidney. Kidney Int 1: 100–105.
    1. Seely JF, Dirks JH. (1977) Site of action of diuretic drugs. Kidney Int 11: 1–8.
    1. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ et al.; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. (2002) Urinary albumin excretion predict cardiovascular and noncardiovascular mortality in general population. Circulation: 106: 1777–82.
    1. Wickman C, Kramer H. (2013) Obesity and kidney disease: potential mechanisms. Semin Nephrol 33: 14–22. 10.1016/j.semnephrol.2012.12.006
    1. Ogna A, Forni Ogna V, Bochud M, Guessous I, Paccaud F, Burnier M et al. (2015) Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes. Eur J Nutr 2015 May14. [Epub ahead of print].
    1. Chiolero A, Maillard M, Nussberger J, Brunner HR, Burnier M. (2000) Proximal sodium reabsorption: An independent determinant of blood pressure response to salt. Hypertension 36: 631–7.
    1. Strazzullo P, Barba G, Cappuccio FP, Siani A, Trevisan M, Farinaro E et al. (2001) Altered renal sodium handling in men with abdominal adiposity: a link to hypertension. J Hypertens 19: 2157–64.
    1. Strazzullo P, Barbato A, Galletti F, Barba G, Siani A, Iacone R et al. (2006) Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study. J Hypertens 24: 1633–9.
    1. Bank N, Aynedjian HS. (1990) Progressive increases in luminal glucose stimulate proximal sodium absorption in normal and diabetic rats. J Clin Invest 86: 309–16.
    1. Hannedouche TP, Delgado AG, Gnionsahe DA, Boitard C, Lacour B, Grunfeld JP. (1990) Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes. Kidney Int 37: 1126–33.
    1. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10: 2569–76.
    1. Vallon V, Blantz RC, Thomson S. (2003) Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 14: 530–7.
    1. Lorenz JN, Schultheis PJ, Traynor T, Shull GE, Schnermann J. (1999) Micropuncture analysis of single-nephron function in NHE3-deficient mice. Am J Physiol. 277(3 Pt 2): F447–53.
    1. Skøtt P, Hommel E, Bruun NE, Arnold-Larsen S, Parving HH. (1988) Effects of acetazolamide on kidney function in type 1 (insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 31: 806–10.
    1. Reiss WG, Oles KS. (1996) Acetazolamide in the treatment of seizures. Ann Pharmacother. 30: 514–9.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere